Exploiting salivary miR-375 as a clinical biomarker of oral potentially malignant disorder

Hsi-Feng Tu a,b,c, Li-Han Lin d, Kuo-Wei Chang b,c, Hui-Wen Cheng d, Chung-Ji Liu b,c,e*

a Department of Dentistry, National Yang Ming Chiao Tung Hospital, Yi-Lan, Taiwan
b Department of Dentistry, College of Dentistry, National Yang Ming Chiao Tung University, Taipei, Taiwan
c Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei, Taiwan
d Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
e Department of Oral and Maxillofacial Surgery, Mackay Memorial Hospital, Taipei, Taiwan

Received 19 August 2021; Final revision received 12 September 2021
Available online 20 September 2021

Keywords Biomarker; miR-375; OPMD; Oral epithelial dysplasia; Saliva

Abstract Background/purpose: Oral potentially malignant disorder (OPMD) is an important premalignancy worldwide. MicroRNAs (miRNAs) are endogenously expressed non-coding RNAs that regulate the post-transcriptional levels of targeted mRNAs. MiRNA-375 (miR-375) is markedly downregulated in oral carcinoma tissues and plays an oncogenic role in oral carcinogenesis. We explored the potential of the deregulated salivary miR-375 levels in OPMD patients.

Materials and methods: We analyzed the levels of miR-375 in the saliva of patients with OPMD (n = 45) and healthy controls (n = 24) by quantitative RT-PCR. The cell lysates and supernatants were treated with the miR-375 mimic and inhibitor.

Results: Salivary miR-375 levels were decreased markedly in the patients with OPMD, compared with the controls. OPMD patients with non-dysplasia showed a higher abundance of miR-375 in the saliva than dysplasia patients, suggesting that salivary miR-375 is a more sensitive marker for OPMD. Patients with malignant transformation during the follow-up period showed lower expression of saliva miR-375 than the others. MiR-375 expression was markedly decreased by treatment with the miR-375 inhibitor, and the supernatants of both NHOK and SAS cells showed a corresponding decline in miR-375 expression.

Conclusion: Our results indicate the potential application of salivary miR-375 as a biomarker for the detection and long-term follow-up of OPMD.

* Corresponding author. Department of Oral and Maxillofacial Surgery, Mackay Memorial Hospital, No. 92, Sec. 2, Chung Shan N. Road, Taipei, 10449, Taiwan. Fax: +886 2 5433642.
E-mail address: cjliu@mmh.org.tw (C.-J. Liu).
† These two authors contributed equally to this study.

https://doi.org/10.1016/j.jds.2021.09.020
1991-7902/© 2021 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Oral potentially malignant disorders (OPMDs) are lesions that correlate with the risk of oral squamous cell carcinoma (OSCC). The overall OPMD transformation rate was estimated at 6.73% in previous studies in Taiwan. A British report indicated that the average overall OPMD transformation rate was 2.6% in 12 years. Interventions for OPMDs are important to prevent OSCC. However, among the diverse and large number of OPMDs, identifying the lesions with the greatest potential for malignant transformation is not easy, but remains very important. Epigenetic changes, especially, noncoding RNA alterations, have drawn more attention in recent cancer research. Compared to the alterations in other noncoding RNAs, microRNA (miRNA) alterations are more intensively characterized in OSCC and head and neck squamous cell carcinoma (HNSCC). However, in the progression of OPMDs, limited miRNA alterations have been reported in malignant transformations. miR-21 and miR-31 were found to be important oncomirs in oral carcinogenesis..

Upregulation of miR-31 was observed in OPMD tissues and correlated with malignant transformation. Increased salivary miR-184 and decreased miR-145 levels were also noted in OPMD patients and found to have a notable diagnostic power. Cervigne et al. stated that the tissue expression of miR-21, miR-181b, and miR-345 is an early event in leukoplakia transforming into malignancy. The altered expression of miRNAs could be a feasible biomarker for determining the potential of malignancy. However, not all progressive premalignant oral lesions were associated with the overexpression of these miRNAs. Critical miRNA alterations occurring in OPMD require vigorous exploration to address the underlying pathogenetic process.

MiR-375 is a well-established tumor suppressor microRNA known to be downregulated in many cancer types, and its downregulation has been suggested to be correlated with tumor size and invasion in OSCC. A low expression level of miR-375 in tongue and laryngeal cancer patients was related to poor of prognosis. Underexpression of miR-375 could lead to uncontrolled CIP2A expression and extended stability of MYC, which contributes to the promotion of oral cancerous phenotypes. As an OSCC suppressor, whether the downregulation of miR-375 occurs in OPMD remains uncertain.

Since the collection and processing of saliva is simple, relatively non-invasive, and cost-effective, it has been used extensively to extract meaningful biological data in different localized and oral diseases. Salivary miRNA biomarkers have recently emerged as a valuable diagnostic method for the detection of oral lesions. The expression of miR-31 significantly increased in the saliva of OPMD patients; miR-31 and epithelial dysplasia are significantly associated with disease progression.

In this study, we further explored the potential of the deregulated levels of miR-375 demonstrated in saliva to serve as biomarkers for the early detection of, and prognostic indicators in OPMD patients.

Materials and methods

Cell culture and reagents

The OSCC cell lines SCC25, SAS, and OECD-1, and normal human oral keratinocytes (NHOKs) were cultured as described previously. The levels of miR-375 in the cultured cells and supernatants were analyzed. NHOKs and SAS were prepared for the further expression study. The miR-375 mimic (C-300682-05), miR-375 inhibitor (IH-300682-07), and negative control (CN-001000-01) were purchased from Dharmaco (Horizon Discovery, Lafayette, CO, USA). A total of 2 x 10^5 NHOK and SAS cells were seeded in a 6-well plate and transfected with 100 nmol/L miR-375 mimic/inhibitor/negative control using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for 24 h. The levels of miR-375 in the cultured cells and supernatants were analyzed.

Saliva samples

These samples were collected after obtaining written informed consent from all the participants, and this study was approved by the Institutional Review Board (IRB) of the Mackay Memorial Hospital (IRB approval numbers 09MMHIS146 and 10MMHIS185). Saliva was collected before surgery from 41 patients with OPMD and 26 matched controls that provided written informed consent. Saliva specimens from 26 healthy individuals matched by age, sex, and oral habits served as the controls. All patients with OPMD underwent total excision and were confirmed by the same pathologist. They were then followed up for at least 5.5 years. No OPMD was diagnosed in the matched controls during the follow-up period. Clinico-pathological parameters of the study subjects are listed in Table 1. Nearly all patients were male, and the vast majority was smokers and/or betel chewers. Eighteen patients were diagnosed as oral epithelial dysplasia, Patients with specific types of OPMD, including oral submucosal fibrosis and erosive lichen planus, were excluded from this study. During the following period there were 5 patients became as OSCC (Table 1).

Two milliliters of saliva were collected from the mouth floor after simple mouth rinsing. After centrifugation, 400 μL of saliva was aliquoted and preserved at −80 °C before use, as described previously.

© 2021 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
miRNA extraction and quantitative-RT-PCR analysis

The supernatant of the cultured cells was collected and centrifuged at 1000 rpm for 5 min to remove potentially contaminating debris and floating cells. The supernatant (400 μL) was aliquoted and preserved at −80 °C. To analyze the cellular miRNAs, the attached cells were harvested by trypsinization and suspended in 400 μL of PBS. miRNAs were then purified from 400 μL of the cell lysates, supernatants, and saliva using the mirVana™ PARIS™ isolation kit (mirVana™, Cat No AM1556, Ambion, Austin, TX, USA). The miR-375 levels in 5 μL of eluate (out of 100 μL) were measured using the TaqMan miRNA assay system (Applied Biosystems, Foster City, CA, USA). Briefly, a looped RT primer specifically paired with miR-375 formed a primer/miR-375-chimera, and the extended oligonucleotide served as a template for subsequent quantitative assays.

Quantitative RT-PCR (qRT-PCR) was performed in triplicate or duplicate using the ABI Prism 7700 Sequence Detector System (Applied Biosystems, Foster City, CA, USA). The expression of U6B served as an internal control. A negative control without a template was amplified in parallel to determine the specificity of the reactions. Ct is the cycle threshold of the signal amplification, and ΔCt represents the difference in Ct values between the miR-375 and U6B levels. Extreme samples, i.e., those with Ct values for U6B beyond 40, were excluded from the analysis.

Statistical analysis

Data are shown as the means or means ± S.E. of triplicate analyses. The sample size of this study was estimated by accessing the PS: Power/Sample Size Calculator version 3.1 (https://biostat.app.vumc.org/wiki/Main/PowerSample Size). SPSS software (version 20.0; IBM, Armonk, New York, USA) was used to perform the statistical analyses. The Mann–Whitney U test was used to compare the differences between the various clinical variants. Statistical significance was set at P < 0.05. To determine the extent to which the obtained −ΔCt could efficiently separate different clinical subsets, receiver operating characteristic (ROC) analysis was performed, and the area under the curve (AUC) was used as a measurement of the separating ability.

Results

Correlation of mir-375 levels between cell lysates and supernatants

To explore whether the concentration of extracellular miR-375 reflected the corresponding changes in NHOK, SCC25, SAS and OECM-1 cells. The results of the in vitro study revealed that the expression level of miR-375 was reduced in OSCC cell lines (SCC25, SAS, and OECM-1), compared with that in the NHOK cells (Fig. 1). qRT-PCR was used to evaluate the expression levels of miR-375 in the cell lysates and supernatants. Transfection with the miR-375 mimic increased miR-375 levels in NHOK and SAS cells (Fig. 2A and C). Likewise, miR-375 mimic-treated cells also had higher supernatant miR-375 levels than the cells treated with the negative control (Fig. 2B and D). When the cellular miR-375 level was significantly decreased by treatment with miR-375 inhibitor (Fig. 2A and C), the miR-375 levels in the supernatants from both the NHOK and SAS cells showed a corresponding decline (Fig. 2B and D).

Decreased mir-375 levels in the saliva of OPMD patients

To investigate whether miR-375 downregulation occurred not only in cytobrushed tumor tissues (as shown in our previous study), but also in the secretome of saliva from patients with OPMD, we analyzed the expression level of miR-375 in the saliva of patients with OPMD and healthy individuals. Regardless of pathological condition, the expression of miR-375 in the saliva of patients with OPMD was significantly lower than that in healthy individuals, as revealed by a mean −ΔCt value of 8.97 in OPMD patients,
compared with a value of 10.17 in the controls (Fig. 3A, Table 2). Differences in the miR-375 levels were found between clinical subsets of patients, such as those with or without dysplasia; this difference was statistically significant (Fig. 3B). In the ROC analyses, when a value of $-\Delta Ct$ of $-10.3$ was used as a cutoff to differentiate the healthy state from the OPMD state, a discrimination power of 0.82 was achieved, with a sensitivity of 0.80 and a specificity of 0.68 (Fig. 3D). In the ROC analyses, when a $-\Delta Ct$ value of $-8.9$ was used as a cutoff to differentiate the non-dysplasia state from the dysplasia state, a discrimination power of 0.77 was attained, with a sensitivity of 0.71 and specificity of 0.83 (Fig. 3E) (see Table 3).

**Decreased miR-375 levels in the saliva of patients with malignant transformation**

We found that 12.2% (5/41) of the OPMD patients presented with OSCC during the follow-up period (Fig. 3C). The mean $-\Delta Ct$ value of the miR-375 levels declined from a $-8.3$ to $-10.2$. The discrimination power for differentiating a patient’s operative status using the ROC analysis was 0.71 when a $-\Delta Ct$ of $-9.5$ was used as the cutoff (Fig. 3F).

**Discussion**

It was found that hazard ratio of the malignant transformation rate was 8.19 times higher in the OPMD group than in the comparison cohort. Data suggested that anyone diagnosed with OPMDs should be closely followed up. The development of new, specific biomarkers is critical to improving the diagnosis and prognosis for patients with such OPMDs. Saliva is in constant contact with oral tissues and is easily obtained using non-invasive methods. These properties make saliva an advantageous source of specimens for the search for potential biomarkers although it may contain serum and desquamated epithelial cells from the oral mucosa, including some leucocytes, especially if there is ulceration or mucositis, the latter being inevitable if a neoplasm is present. Because of the stability of their structures, miRNAs may exist stably even in harsh biological...
environments, for example, within the saliva, plasma, or other body fluids. This characteristic makes salivary miRNAs an emerging field for monitoring not only oral diseases but also systemic diseases and general health. The lack of well-characterized or matched clinical groups and lack of suitable endogenous

**Table 2** - ΔCt values of miR-375 expression in the saliva of OPMD patients and controls.

|                   | OPMD (n = 41) | Control (n = 26) | p value^a |
|-------------------|--------------|------------------|-----------|
| All               | -ΔCt (Mean ± SE) | -ΔCt (Mean ± SE) |           |
| Dysplasia (n = 18) | 8.97 ± 0.37  | 10.17 ± 0.33     | 0.020^b   |
|                   | 7.87 ± 0.5   | 10.17 ± 0.33     | <0.001^c  |

Abbreviations: OPMD, oral potentially malignant disorder.
a ΔCt: difference in cycle threshold values between detected miRNAs and U6B.
b Comparison of salivary miR-375 levels across OPMD patients and controls.
c Comparison of salivary miR-375 levels across dysplasia patients and controls.

**Table 3** - ΔCt values of miR-375 expression in the saliva of OPMD patients.

|                   | -ΔCt (Mean ± SE) | p value^a |
|-------------------|------------------|-----------|
| Dysplasia (n = 18) | 7.87 ± 0.5       | 0.003^b   |
| Non-dysplasia (n = 23) | 9.83 ± 0.34   |           |
| Malignant transformation (n = 5) | 7.54 ± 0.25 | 0.04^c   |
| Non-malignant transformation (n = 36) | 9.11 ± 0.37 |           |

Abbreviation: OPMD, oral potentially malignant disorder.
a ΔCt: difference in cycle threshold values between detected miRNAs and U6B.
b Comparison of salivary miR-375 in dysplasia patients and non-dysplasia patients.
c Comparison of salivary miR-375 levels in OPMD patients with malignant transformation and Non-malignant transformation.

**Figure 3** Salivary miR-375 expression in controls and patients with oral premalignant disorder (OPMD). Q-RT-PCR analysis was performed to detect the expression levels of miR-375 in saliva samples from control subjects and OPMD patients (A), subjects with non-dysplasia and dysplasia (B), and subjects with non-malignant change and malignant transformation (C). Receiver operating characteristic (ROC) analysis of saliva samples from control subjects and OPMD patients (D), subjects with non-dysplasia and dysplasia (E), and subjects with non-malignant change and malignant transformation (F).
controls for extracellular miRNA detection in saliva and the need for normalization are among the major restrictions associated with utilizing salivary miRNAs for biomarker discovery. Therefore, we used gender, age, and oral habit-matched controls from various populations to identify appropriate salivary miRNA biomarkers, so that population-specific and habit-specific miRNA signatures in OPMD patients could be elucidated.

Studies on salivary miRNA expression in OPMD are sparse, given that miRNA expression studies associated with oral cancer began only in 2009. Several studies on salivary miRNAs were performed in OPMD, and several miRNAs were found to be deregulated in OPMD, in contrast with miR-145, which was underexpressed in OPMD. There have been no definite studies to evaluate miR-375 expression in the saliva of OPMD patients. Previous studies have shown a marked decrease in miR-375 expression in tissues and plasma from patients with OSCC, compared with that in healthy individuals. In tissue samples, the expression level of miR-375 was significantly higher in nonprogressive premalignant lesions than in progressive premalignant lesions. Moreover, miR-375 expression was significantly lower after the progression to OSCC in all the samples. This is the first time that salivary miR-375 was found to be expressed in OPMD. Aberrant salivary miR-375 expression could be detected in OPMD patients and distinguish them from matched control volunteers and dysplasia patients from subjects without dysplasia, suggesting a potential clinical application for oral lesion-specific miRNA signatures in saliva. This is a convenient and less invasive method that highlights miR-375 as a biomarker for OPMD.

Since salivary fluid consists of cellular debris and degraded RNAs, the supernatant is probably a better sample for assaying cell-free nucleic acids. Moreover, exosome enrichment followed by miRNA isolation further reduced the variability in expression profiles among samples due to the removal of degraded RNAs. In a previous cytobrushing study, miR-375 was derived directly and mainly from tumor tissue. This was supported by direct evidence from our in vitro study, which showed that the expression of miR-375 in the supernatant decreased after the inhibition of intracellular miR-375 expression in cells. These results suggest the potential application of salivary miR-375 in monitoring or detecting residual or recurrent OSCC.

Downregulated miR-375 levels in saliva could be detected even from different types of oral lesions, including dysplasia, and the sensitivity of detection of such lesions was not different from the detection of the severity of the dysplasia. This suggests that because of its abundance, salivary miR-375 could potentially be exploited to detect and diagnose insidious oral precancerous lesions in at-risk populations. A recent study showed a notable decrease in the levels of miR-200a and miR-125a in the saliva of patients with tongue cancers. Although the origin and clinical significance of these two salivary miRNAs showing decreased expression in OSCC remain to be determined, measuring the levels of salivary miRNAs in patients with OSCC by qRT-PCR appears to be a promising approach to identify new biomarkers in saliva. The discovery and combination of multiple salivary miRNAs may provide a better power of discrimination for the diagnosis of OPMD and follow-up of OPMD patients. Considering that the origins of salivary and plasma miRNAs may be similar, decreases in plasma and salivary miR-375 levels may have clinical or pathological implications. However, the high correlation between them suggests that the combined use of both salivary and plasma markers may also enable a more powerful prediction of OPMD.

Declaration of competing interest

The authors have no conflicts of interest relevant to this article.

Acknowledgments

This study was supported by grants MMH-E-108-12 from MacKay Memorial Hospital, Taiwan. MOST 108-2314-B-010-014, MOST 108-2314-B-195-002-MY2, and 110-2314-B-195-015-MY3 from the Ministry of Science and Technology, Taiwan, and MOHW110-TDU-B-211-144019 from the Ministry of Health and Welfare, Taiwan. We wish to thank Dr. Liu, Ko-Jiun and Dr. Shiah, Shine-Gwo for their comments in this study.

References

1. Wang YY, TaiY H, Wang WC, et al. Malignant transformation in 5071 southern Taiwanese patients with potentially malignant oral mucosal disorders. BMC Oral Health 2014;14: e99.
2. Hsue SS, Wang WC, Chen CH, et al. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital. J Oral Pathol Med 2007;36:25–9.
3. Chiu SF, Ho CH, Chen YC, et al. Malignant transformation of oral potentially malignant disorders in Taiwan: an observational nationwide population database study. Medicine (Baltimore) 2021;100:e24934.
4. Yang PY, Chang YC. An update of oral potentially malignant disorders and their malignant transformation into oral cancers in Taiwan. J Dent Sci 2021;16:774–5.
5. Warnakulasuriya S, Kovacevic T, Madden P, et al. Factors predicting malignant transformation in oral potentially malignant disorders among patients accrued over a 10-year period in South East England. J Oral Pathol Med 2011;40:677–83.
6. Uma Maheswari TH, Niveditha MS, Ramani P. Expression profile of salivary micro RNA-21 and 31 in oral potentially malignant disorders. Braz Oral Res 2020;34:e002.
7. Hung PS, Tu HF, Kao SY, et al. miR-31 is upregulated in oral premalignant epithelium and contributes to the immortalization of normal oral keratinocytes. Carcinogenesis 2014;35:1162–71.
8. Hung KF, Liu CJ, Chiu PC, et al. MicroRNA-31 upregulation predicts increased risk of progression of oral potentially malignant disorder. Oral Oncol 2016;53:42–7.
9. Maheswari TNU, Venugopal A, Sureshbabu NM, Ramani P. Salivary micro RNA as a potential biomarker in oral potentially malignant disorders: a systematic review. Ci Ji Yi Xue Za Zhi 2018;30:55–60.
10. Cervigne NK, Reis PP, Machado J, et al. Identification of a microRNA signature associated with progression of leukoplaikia to oral carcinoma. Hum Mol Genet 2009;18:4818–29.
11. Yan JW, Lin JS, He XX. The emerging role of miR-375 in cancer. 
   Int J Canc 2014;135:1011–8.
12. Slow MY, Ng LP, Vincent-Chong VK, et al. Dysregulation of miR-
   31 and miR-375 expression is associated with clinical outcomes 
   in oral carcinoma. Oral Dis 2014;20:345–51.
13. Jia L, Huang Y, Zheng Y, et al. miR-375 inhibits cell growth and 
   correlates with clinical outcomes in tongue squamous cell 
   carcinoma. Oncol Rep 2015;33:2061–71.
14. Chang K, Wei Z, Cao H. miR-375-3p inhibits the progression of 
   laryngeal squamous cell carcinoma by targeting hepatocyte 
   nuclear factor-1beta. Oncol Lett 2020;20:80.
15. Jung HM, Patel RS, Phillips BL, et al. Tumor suppressor miR-375 
   regulates MYC expression via repression of CIP2A coding 
   sequence through multiple miRNA-mRNA interactions. Mol Biol 
   Cell 2013;24:1638–48. S1–7.
16. Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW. Exploiting 
   salivary miR-31 as a clinical biomarker of oral squamous cell 
   carcinoma. Head Neck 2012;34:219–24.
17. Lin SC, Lin LH, Yu SY, et al. FAT1 somatic mutations in head and 
   neck carcinoma are associated with tumor progression and 
   survival. Carcinogenesis 2018;39:1320–30.
18. Park NJ, Yu T, Nabilv V, et al. RNAprotect saliva: an optimal 
   room-temperature stabilization reagent for the salivary tran-
   scriptome. Clin Chem 2006;52:2303–4.
19. Hu S, Arellano M, Boontheung P, et al. Salivary proteomics for oral 
   cancer biomarker discovery. Clin Canc Res 2008;14:6246–52.
20. Li Y, St John MA, Zhou X, et al. Salivary transcriptome diagnostics 
   for oral cancer detection. Clin Canc Res 2004;10:8442–50.
21. Liu CJ, Kao SY, Tu HF, et al. Increase of microRNA miR-31 level 
   in plasma could be a potential marker of oral cancer. Oral Dis 
   2010;16:360–4.
22. Liu CJ, Tsai MM, Hung PS, et al. miR-31 ablates expression of 
   the HIF regulatory factor FIH to activate the HIF pathway in 
   head and neck carcinoma. Canc Res 2010;70:1635–44.
23. Chang KW, Liu CJ, Chu TH, et al. Association between high 
   miR-211 microRNA expression and the poor prognosis of oral 
   carcinoma. J Dent Res 2008;87:1063–8.
24. Ng EK, Chong WW, Jin H, et al. Differential expression of 
   microRNAs in plasma of colorectal cancer patients: a 
   potential marker for colorectal cancer screening. Gut 2009; 
   58:1375–81.
25. Tu HF, Chang KW, Lin SC, et al. Aberrant miR-10b, miR-372, 
   and miR-375 expression in the cytobrushed samples from oral 
   potentially malignant disorders. J Dent Sci 2022;17:688–95.
26. Humphrey SP, Williamson RT. A review of saliva: normal compo-
   sition, flow, and function. J Prosthett Dent 2001;85:162–9.
27. Shpitzer T, Hamzany Y, Bahar G, et al. Salivary analysis of oral 
   cancer biomarkers. Br J Canc 2009;101:1194–8.
28. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in 
   serum: a novel class of biomarkers for diagnosis of cancer and 
   other diseases. Cell Res 2008;18:997–1006.
29. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as 
   stable blood-based markers for cancer detection. Proc Natl 
   Acad Sci U S A 2008;105:10513–8.
30. Bonne NJ, Wong DT. Salivary biomarker development using 
   genomic, proteomic and metabolomic approaches. Genome 
   Med 2012;4:e82.
31. Yoshizawa JM, Wong DT. Salivary microRNAs and oral cancer 
   detection. Methods Mol Biol 2013;936:313–24.
32. Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, 
   characterization, and clinical utility for oral cancer 
   detection. Clin Canc Res 2009;15:5473–7.
33. Momen-Heravi F, Trachtenberg AJ, Kuo WP, Cheng YS. 
   Genonewide study of salivary microRNAs for detection of oral 
   cancer. J Dent Res 2014;93(suppl 7):S86–93.
34. Zahran F, Ghalwash D, Shaker O, Al-Johani K, Scully C. Salivary 
   microRNAs in oral cancer. Oral Dis 2015;21:739–47.
35. Wu Y, Sun X, Song B, Qiu X, Zhao J. MiR-375/LC7A11 axis 
   regulates oral squamous cell carcinoma proliferation and in-
   vasion. Cancer Med 2017;6:1686–97.
36. Harris T, Jimenez L, Kawachi N, et al. Low-level expression of 
   miR-375 correlates with poor outcome and metastasis while 
   altering the invasive properties of head and neck squamous 
   cell carcinomas. Am J Pathol 2012;180:917–28.
37. Harrandah AM, Fitzpatrick SG, Smith MH, et al. MicroRNA-375 
   as a biomarker for malignant transformation in oral lesions. 
   Oral Surg Oral Med Oral Pathol Oral Radiol 2016;122: 
   743–752 e1.